{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:46Z","timestamp":1790908546201,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Despite therapeutic advances and improved survival, the long\u2010term economic burden of chronic myeloid leukaemia (CML) remains under\u2010recognised given evolving treatment practices and fluctuating drug costs. We aimed to estimate and project total prevalence costs for CML in Sweden from a healthcare sector perspective, representing the direct healthcare expenditures for all patients living with CML, based on real\u2010world drug and procedure prices. We used data from the Swedish Cancer Register and the Swedish CML register to estimate and project prevalence and costs. The estimated numbers of prevalent cases were 1808 (95% confidence interval [CI], 1604\u20132011) in 2025 and 2120 (95% CI, 1916\u20132325) in 2030, driven by stable incidence and improved survival. Despite increasing prevalence, the annual total direct healthcare costs for all prevalent CML patients in Sweden decreased from USD 40.04 million (95% CI, 33.70\u201346.40) in 2015 to USD 26.04 million (95% CI, 23.13\u201328.97) in 2025, then projected to slightly increase to USD 30.67 million (95% CI, 27.70\u201333.64) in 2030. While CML prevalence proportions are expected to increase, declining treatment costs may mitigate the burden on the Swedish healthcare system. These population\u2010based projections can inform long\u2010term planning and pricing strategies for CML care.<\/jats:p>","DOI":"10.1111\/bjh.70193","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:29:41Z","timestamp":1759894181000},"page":"2441-2450","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population\u2010based study"],"prefix":"10.1111","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-708X","authenticated-orcid":false,"given":"Enoch Yi\u2010Tung","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Dickman","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7779-7297","authenticated-orcid":false,"given":"Fabrizio","family":"Di Mari","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Dahl\u00e9n","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Hematology Karolinska University Hospital Solna  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[{"name":"Department of Hematology Karolinska University Hospital Solna  Stockholm Sweden"},{"name":"Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[{"name":"Department of Hematology Karolinska University Hospital Solna  Stockholm Sweden"},{"name":"Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12743"},{"key":"e_1_2_9_4_1","unstructured":"Dahl\u00e9nT OlssonK SandinF.Chronic myeloid leukemia (CML) \u2010 national quality report for 2023 (In Swedish: Kronisk myeloisk leukemi (KML) \u2010 Nationell kvalitetsrapport f\u00f6r 2023).2024."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.953141"},{"key":"e_1_2_9_6_1","unstructured":"The Dental and Pharmaceutical Benefits Agency (In Swedish: Tandv\u00e5rds\u2010 och l\u00e4kemedelsf\u00f6rm\u00e5nsverket TLV).The development of pharmaceutical expenditure in Sweden \u2013 managed entry agreements is an increasingly important tool for cost control as well as for early and equal access. Report No.: 3610\/2017.2017."},{"key":"e_1_2_9_7_1","unstructured":"The Dental and Pharmaceutical Benefits Agency (In Swedish: Tandv\u00e5rds\u2010 och l\u00e4kemedelsf\u00f6rm\u00e5nsverket TLV).Dasatinib Sandoz is included in the high\u2010cost coverage with limitation (Swedish: Dasatinib Sandoz ing\u00e5r i h\u00f6gkostnadsskyddet med begr\u00e4nsning).2020."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2017.0602.016"},{"key":"e_1_2_9_9_1","unstructured":"The Dental and Pharmaceutical Benefits Agency (In Swedish: Tandv\u00e5rds\u2010 och l\u00e4kemedelsf\u00f6rm\u00e5nsverket TLV).Underlag f\u00f6r beslut om subvention \u2010 Nyans\u00f6kan N\u00e4mnden f\u00f6r l\u00e4kemedelsf\u00f6rm\u00e5ner\u2010\u2010Scemblix (asciminib) [Internet].2023. Available from:https:\/\/www.tlv.se\/download\/18.187f44431872c3a93f232608\/1680255944998\/bes230323_scemblix_3266\u20102022_underlag.pdf"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2604-x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17392"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000496"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32137"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.12.1494"},{"key":"e_1_2_9_19_1","unstructured":"Max Planck Institute for Demographic Research (Germany) University of California Berkeley (USA) French Institute for Demographic Studies (France).Human mortality database [Internet]. Available from:www.mortality.org"},{"key":"e_1_2_9_20_1","unstructured":"The Dental and Pharmaceutical Benefits Agency (In Swedish: Tandv\u00e5rds\u2010 och l\u00e4kemedelsf\u00f6rm\u00e5nsverket TLV).TLV's price and decision database (In Swedish: TLV:s pris\u2010 och beslutsdatabas) [Internet]. Available from:https:\/\/www.tlv.se\/ovriga\u2010sidor\/sok\u2010i\u2010databasen.html"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.208"},{"key":"e_1_2_9_22_1","unstructured":"Karolinska University Hospital (In Swedish: Karolinska Universitetssjukhuset).Extra\u2010regional pricing list for EU\/EEA and Switzerland (In Swedish: Utomregional prislista samt f\u00f6r EU\/EES och Schweiz) Karolinska Universitetssjukhuset.2025."},{"key":"e_1_2_9_23_1","unstructured":"Karolinska University Hospital (In Swedish: Karolinska Universitetssjukhuset).National price list for laboratory medical services (In Swedish: Nationell Prislista f\u00f6r Laboratoriemedicinsk Service).2024."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780080207"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_2_9_26_1","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer F","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500112"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2011.01640.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3064"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14328"},{"key":"e_1_2_9_31_1","unstructured":"Statistics Sweden (In Swedish: Statistikmyndigheten).Consumer price index fixed index numbers (1980=100). [cited 2025 March 28] [Internet]. Available from:https:\/\/www.scb.se\/en\/finding\u2010statistics\/statistics\u2010by\u2010subject\u2010area\/prices\u2010and\u2010economic\u2010trends\/price\u2010statistics\/consumer\u2010price\u2010index\u2010cpi\/pong\/tables\u2010and\u2010graphs\/consumer\u2010price\u2010index\u2010cpi\/cpi\u2010fixed\u2010index\u2010numbers\u20101980100\/"},{"key":"e_1_2_9_32_1","unstructured":"Sweden Central Bank (In Swedish: Riksbanken).Annual average exchange rates. [cited 2025 March 28] [Internet]. Available from:https:\/\/www.riksbank.se\/en\u2010gb\/statistics\/search\u2010interest\u2010\u2010exchange\u2010rates\/annual\u2010average\u2010exchange\u2010rates\/"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.04.008"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495598"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2306"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02398-6"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T11:44:23Z","timestamp":1767959063000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/bjh.70193"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70193","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"2025-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}